Short-term Health-related Quality of Life Consequences in a Lung Cancer CT Screening Trial (NELSON)
Overview
Authors
Affiliations
Background: In lung cancer CT screening, participants often have an indeterminate screening result at baseline requiring a follow-up CT. In subjects with either an indeterminate or a negative result after screening, we investigated whether health-related quality of life (HRQoL) changed over time and differed between groups in the short term.
Methods: A total of 733 participants in the NELSON trial received four questionnaires: T0, before randomisation; T1, 1 week before the baseline screening; T2, 1 day after the screening; and T3, 2 months after the screening results but before the 3-month follow-up CT. HRQoL was measured as generic HRQoL (the 12-item Short Form, SF-12; the EuroQol questionnaire, EQ-5D), anxiety (the Spielberger State-Trait Anxiety Inventory, STAI-6), and lung-cancer-specific distress (the Impact of Event Scale, IES). For analyses, repeated-measures analysis of variance was used, adjusted for covariates.
Results: Response to each questionnaire was 88% or higher. Scores on SF-12, EQ-5D, and STAI-6 showed no clinically relevant changes over time. At T3, IES scores that were clinically relevant increased after an indeterminate result, whereas these scores showed a significant decrease after a negative result. At T3, differences in IES scores between the two baseline result groups were both significant and clinically relevant (P<0.01).
Conclusion: This longitudinal study among participants of a lung cancer screening programme showed that in the short term recipients of an indeterminate result experienced increased lung-cancer-specific distress, whereas the HRQoL changes after a negative baseline screening result may be interpreted as a relief.
Wu J, Zhuang W, Chen R, Xu H, Li Z, Lan Z Qual Life Res. 2025; .
PMID: 39812961 DOI: 10.1007/s11136-024-03876-w.
Hemmati M, Ishizawa S, Meza R, Ostrin E, Hanash S, Antonoff M EClinicalMedicine. 2025; 74:102743.
PMID: 39764179 PMC: 11701438. DOI: 10.1016/j.eclinm.2024.102743.
McFadden K, Nickel B, Rankin N, Li T, Jennett C, Sharman A Cancer Med. 2024; 13(15):e70054.
PMID: 39096118 PMC: 11297455. DOI: 10.1002/cam4.70054.
The pros and cons of lung cancer screening.
Ledda R, Funk G, Sverzellati N Eur Radiol. 2024; 35(1):267-275.
PMID: 39014085 PMC: 11632016. DOI: 10.1007/s00330-024-10939-6.
Hardavella G, Frille A, Chalela R, Sreter K, Petersen R, Novoa N Eur Respir Rev. 2024; 33(172).
PMID: 38925794 PMC: 11216686. DOI: 10.1183/16000617.0232-2023.